MXPA04004219A - Derivados de quinazolina como agentes antitumorales. - Google Patents
Derivados de quinazolina como agentes antitumorales.Info
- Publication number
- MXPA04004219A MXPA04004219A MXPA04004219A MXPA04004219A MXPA04004219A MX PA04004219 A MXPA04004219 A MX PA04004219A MX PA04004219 A MXPA04004219 A MX PA04004219A MX PA04004219 A MXPA04004219 A MX PA04004219A MX PA04004219 A MXPA04004219 A MX PA04004219A
- Authority
- MX
- Mexico
- Prior art keywords
- quinazoline derivatives
- antitumor agents
- tumours
- medicament
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
La invencion concierne a derivados de quinazolina de la formula (I); en donde cada uno de Q1, Z, R1 y Q2 tienen cualquiera de los significados definidos en la descripcion; procesos para su preparacion, composiciones farmaceuticas que los que contienen y su uso en la manufactura de un medicamento para usarse en la prevencion o tratamiento de tumores que son sensibles a la inhibicion de tirosincinasas del receptor erbB.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0126433.2A GB0126433D0 (en) | 2001-11-03 | 2001-11-03 | Compounds |
GB0129059A GB0129059D0 (en) | 2001-12-05 | 2001-12-05 | Compounds |
PCT/GB2002/004931 WO2003040108A1 (en) | 2001-11-03 | 2002-10-31 | Quinazoline derivatives as antitumor agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04004219A true MXPA04004219A (es) | 2004-09-10 |
Family
ID=26246737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04004219A MXPA04004219A (es) | 2001-11-03 | 2002-10-31 | Derivados de quinazolina como agentes antitumorales. |
Country Status (23)
Country | Link |
---|---|
US (2) | US20050043336A1 (es) |
EP (1) | EP1444210B1 (es) |
JP (1) | JP2005515176A (es) |
KR (1) | KR20050042055A (es) |
CN (1) | CN100343238C (es) |
AR (1) | AR037330A1 (es) |
AT (1) | ATE423104T1 (es) |
BR (1) | BR0213842A (es) |
CA (1) | CA2465068A1 (es) |
CO (1) | CO5580774A2 (es) |
DE (1) | DE60231230D1 (es) |
ES (1) | ES2320980T3 (es) |
HK (1) | HK1066218A1 (es) |
HU (1) | HUP0401646A2 (es) |
IL (1) | IL161619A0 (es) |
IS (1) | IS7240A (es) |
MX (1) | MXPA04004219A (es) |
NO (1) | NO20042279L (es) |
NZ (1) | NZ532524A (es) |
PL (1) | PL369938A1 (es) |
RU (1) | RU2004116911A (es) |
TW (1) | TW200301702A (es) |
WO (1) | WO2003040108A1 (es) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2441501C (en) * | 2001-03-23 | 2010-09-14 | Bayer Corporation | Rho-kinase inhibitors |
UY27224A1 (es) * | 2001-03-23 | 2002-10-31 | Bayer Corp | Inhibidores de la rho-quinasa |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
BR0307151A (pt) * | 2002-02-01 | 2004-12-07 | Astrazeneca Ab | Composto ou um sal do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso do composto ou de um seu sal, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, como um ser humano, que necessita de um tratamento do tipo referido, e, processos para a preparação de 5-bromo-7- azaindol, e para a produção de 5-metóxi-7-azaindol |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
AU2003292435A1 (en) * | 2002-12-23 | 2004-07-14 | Astrazeneca Ab | 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents |
TW200503994A (en) * | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
JP2007501854A (ja) * | 2003-05-27 | 2007-02-01 | ファイザー・プロダクツ・インク | 受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド[3,4−d]ピリミジン類 |
CA2733145C (en) * | 2003-07-02 | 2012-06-19 | Corus Pharma, Inc. | Aztreonam l-lysine and method of determining impurities therein |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
PT1660090E (pt) * | 2003-08-14 | 2013-01-11 | Array Biopharma Inc | Análogos de quinazolina como inibidores de tirosina-cinases recetoras |
US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
MXPA06002963A (es) * | 2003-09-16 | 2006-06-14 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de cinasa de tirosina. |
BRPI0414489A8 (pt) * | 2003-09-16 | 2019-01-15 | Astrazeneca Ab | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina |
DE602004022180D1 (de) * | 2003-09-16 | 2009-09-03 | Astrazeneca Ab | Chinazolinderivate |
GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
CA2541100A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazenca Ab | Quinazoline derivatives |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
US20050171172A1 (en) * | 2003-11-13 | 2005-08-04 | Ambit Biosciences Corporation | Amide derivatives as PDGFR modulators |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
EP2371364B1 (en) | 2004-01-22 | 2016-10-19 | University of Miami | Topical or intravenous co-enzyme q10 formulations for use in treating cancer |
AU2005207946A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
JP4932495B2 (ja) | 2004-01-23 | 2012-05-16 | アムゲン インコーポレイテッド | 化合物及び使用方法 |
EP1713781B1 (en) | 2004-02-03 | 2008-11-05 | AstraZeneca AB | Quinazoline derivatives |
FR2866887A1 (fr) * | 2004-02-27 | 2005-09-02 | Oreal | Para-phenylenediamine secondaire n-heteroaryle, compositon tinctoriale comprenant une telle para-phenylenediamine, procede mettant en oeuvre cette composition et utilisation |
NZ550796A (en) | 2004-05-06 | 2010-07-30 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides |
US20070232607A1 (en) * | 2004-06-04 | 2007-10-04 | Bradbury Robert H | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases |
JP2008513463A (ja) | 2004-09-15 | 2008-05-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チアゾロピリジンキナーゼ阻害剤 |
AU2005293336B2 (en) | 2004-10-12 | 2009-05-28 | Astrazeneca Ab | Quinazoline derivatives |
JP2008521900A (ja) | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
US7576098B2 (en) * | 2004-12-08 | 2009-08-18 | Bristol-Myers Squibb Company | Heterocyclic compounds as inhibitors of factor VIIa |
US7947676B2 (en) * | 2004-12-14 | 2011-05-24 | Astrazeneca Ab | Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents |
CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
WO2006081741A1 (fr) * | 2005-02-05 | 2006-08-10 | Piaoyang Sun | Dérivés de quinazoline ou leurs sels de qualité pharmaceutique, synthèse et applications médicales desdites substances |
GB0504475D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
WO2006118749A1 (en) * | 2005-05-04 | 2006-11-09 | Janssen Pharmaceutica, N.V. | Thia-tetraazaacenaphthylene kinase inhibitors |
WO2007034143A1 (en) * | 2005-09-20 | 2007-03-29 | Astrazeneca Ab | Quinazoline derivatives as anticancer agents |
WO2007034144A1 (en) * | 2005-09-20 | 2007-03-29 | Astrazeneca Ab | 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
US8648087B2 (en) * | 2005-11-15 | 2014-02-11 | Array Biopharma, Inc. | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
JP2009517450A (ja) | 2005-12-02 | 2009-04-30 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害薬としての4−アニリノ置換キナゾリン誘導体 |
CN101321739A (zh) * | 2005-12-02 | 2008-12-10 | 阿斯利康(瑞典)有限公司 | 用作erbB酪氨酸激酶抑制剂的喹唑啉衍生物 |
UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
JP2009544609A (ja) * | 2006-07-18 | 2009-12-17 | アストラゼネカ・アクチエボラーグ | 置換2−アセチルアミノ−アルコキシフェニルの製造方法 |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
FR2912145B1 (fr) * | 2007-02-02 | 2009-03-06 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CA2677336A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
JP5516397B2 (ja) * | 2007-04-05 | 2014-06-11 | アムジエン・インコーポレーテツド | オーロラキナーゼ調節物質及び使用方法 |
EP2220054A2 (en) | 2007-10-29 | 2010-08-25 | Natco Pharma Limited | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents |
EP2220078B1 (en) * | 2007-10-29 | 2013-05-22 | Amgen, Inc | Benzomorpholine derivatives and methods of use |
NZ586582A (en) | 2008-02-07 | 2012-07-27 | Boehringer Ingelheim Int | Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production |
EP2271325A4 (en) | 2008-04-11 | 2011-11-09 | Cytotech Labs Llc | METHODS AND USE OF INDUCING APOPTOSIS IN CANCER CELLS |
ES2444128T3 (es) | 2008-05-13 | 2014-02-24 | Astrazeneca Ab | Nueva SAL-554 |
JP5539351B2 (ja) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法 |
EA201101519A1 (ru) | 2009-05-11 | 2012-10-30 | БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи | Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния |
ES2762451T3 (es) | 2011-04-04 | 2020-05-25 | Berg Llc | Tratamiento de tumores del sistema nervioso central con coenzima Q10 |
CN105338973A (zh) | 2013-04-08 | 2016-02-17 | 博格有限责任公司 | 使用辅酶q10联合疗法治疗癌症 |
EP3041496B1 (en) | 2013-09-04 | 2020-04-29 | Berg LLC | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
JP6527513B2 (ja) | 2013-11-20 | 2019-06-05 | シグナルケム・ライフサイエンシーズ・コーポレイションSignalchem Lifesciences Corporation | Tamファミリーキナーゼ阻害剤としてのキナゾリン誘導体 |
WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
CN106831599B (zh) * | 2017-03-03 | 2019-08-23 | 南京理工大学 | 一种合成1-二氟甲基咪唑及其衍生物的方法 |
CN107400094B (zh) * | 2017-09-08 | 2020-04-03 | 贾玉庆 | 喹唑啉基羧酸酯类化合物及其用途 |
CN108285421A (zh) * | 2018-01-26 | 2018-07-17 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成拉帕替尼中间体的方法 |
TW202344253A (zh) * | 2018-05-08 | 2023-11-16 | 大陸商迪哲(江蘇)醫藥股份有限公司 | ErbB受體抑制劑 |
CA3099776A1 (en) * | 2018-09-18 | 2020-03-26 | Suzhou Zanrong Pharma Limited | Quinazoline derivatives as antitumor agents |
CN109336828B (zh) * | 2018-11-30 | 2022-04-26 | 雅安职业技术学院 | 一种喹唑啉衍生物及其制备方法和应用 |
CN113200945A (zh) * | 2021-04-23 | 2021-08-03 | 上海应用技术大学 | 一种芳香胺化合物的制备方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
CA1340821C (en) * | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (es) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
AU1721697A (en) * | 1996-01-31 | 1997-08-22 | Gist-Brocades B.V. | Use of compositions comprising stabilized biologically effective compounds |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
WO1998002434A1 (en) * | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US5929080A (en) * | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
US6384223B1 (en) * | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
US7176312B2 (en) * | 2001-10-12 | 2007-02-13 | The Scripps Research Institute | Kinase inhibitor scaffolds and methods for their preparation |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
UY28441A1 (es) * | 2003-07-29 | 2005-02-28 | Astrazeneca Ab | Derivados de quinazolina |
MXPA06002963A (es) * | 2003-09-16 | 2006-06-14 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de cinasa de tirosina. |
BRPI0414489A8 (pt) * | 2003-09-16 | 2019-01-15 | Astrazeneca Ab | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina |
DE602004022180D1 (de) * | 2003-09-16 | 2009-09-03 | Astrazeneca Ab | Chinazolinderivate |
GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
ES2281007T3 (es) * | 2003-09-19 | 2007-09-16 | Astrazeneca Ab | Derivados de quinazolina. |
BRPI0414735A (pt) * | 2003-09-25 | 2006-11-21 | Astrazeneca Ab | derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
EP1713781B1 (en) * | 2004-02-03 | 2008-11-05 | AstraZeneca AB | Quinazoline derivatives |
US20070232607A1 (en) * | 2004-06-04 | 2007-10-04 | Bradbury Robert H | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases |
-
2002
- 2002-10-31 DE DE60231230T patent/DE60231230D1/de not_active Expired - Lifetime
- 2002-10-31 ES ES02774960T patent/ES2320980T3/es not_active Expired - Lifetime
- 2002-10-31 CN CNB028263847A patent/CN100343238C/zh not_active Expired - Fee Related
- 2002-10-31 HU HU0401646A patent/HUP0401646A2/hu unknown
- 2002-10-31 JP JP2003542154A patent/JP2005515176A/ja not_active Ceased
- 2002-10-31 US US10/494,137 patent/US20050043336A1/en not_active Abandoned
- 2002-10-31 CA CA002465068A patent/CA2465068A1/en not_active Abandoned
- 2002-10-31 NZ NZ532524A patent/NZ532524A/en unknown
- 2002-10-31 KR KR1020047006709A patent/KR20050042055A/ko not_active Application Discontinuation
- 2002-10-31 MX MXPA04004219A patent/MXPA04004219A/es unknown
- 2002-10-31 AT AT02774960T patent/ATE423104T1/de not_active IP Right Cessation
- 2002-10-31 IL IL16161902A patent/IL161619A0/xx unknown
- 2002-10-31 PL PL02369938A patent/PL369938A1/xx not_active Application Discontinuation
- 2002-10-31 RU RU2004116911/04A patent/RU2004116911A/ru not_active Application Discontinuation
- 2002-10-31 BR BR0213842-5A patent/BR0213842A/pt not_active IP Right Cessation
- 2002-10-31 EP EP02774960A patent/EP1444210B1/en not_active Expired - Lifetime
- 2002-10-31 WO PCT/GB2002/004931 patent/WO2003040108A1/en active Application Filing
- 2002-11-01 AR ARP020104181A patent/AR037330A1/es not_active Application Discontinuation
- 2002-11-01 TW TW091132367A patent/TW200301702A/zh unknown
-
2004
- 2004-04-30 IS IS7240A patent/IS7240A/is unknown
- 2004-06-02 NO NO20042279A patent/NO20042279L/no not_active Application Discontinuation
- 2004-06-02 CO CO04051621A patent/CO5580774A2/es not_active Application Discontinuation
- 2004-11-18 HK HK04109119.3A patent/HK1066218A1/xx not_active IP Right Cessation
-
2006
- 2006-05-31 US US11/443,208 patent/US20070082921A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR037330A1 (es) | 2004-11-03 |
KR20050042055A (ko) | 2005-05-04 |
DE60231230D1 (de) | 2009-04-02 |
NZ532524A (en) | 2007-02-23 |
NO20042279L (no) | 2004-06-02 |
US20070082921A1 (en) | 2007-04-12 |
BR0213842A (pt) | 2004-08-31 |
US20050043336A1 (en) | 2005-02-24 |
HUP0401646A2 (hu) | 2004-12-28 |
IL161619A0 (en) | 2004-09-27 |
ATE423104T1 (de) | 2009-03-15 |
CN100343238C (zh) | 2007-10-17 |
WO2003040108A1 (en) | 2003-05-15 |
RU2004116911A (ru) | 2005-11-10 |
CN1585754A (zh) | 2005-02-23 |
JP2005515176A (ja) | 2005-05-26 |
CO5580774A2 (es) | 2005-11-30 |
ES2320980T3 (es) | 2009-06-01 |
PL369938A1 (en) | 2005-05-02 |
EP1444210A1 (en) | 2004-08-11 |
IS7240A (is) | 2004-04-30 |
CA2465068A1 (en) | 2003-05-15 |
TW200301702A (en) | 2003-07-16 |
EP1444210B1 (en) | 2009-02-18 |
HK1066218A1 (en) | 2005-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04004219A (es) | Derivados de quinazolina como agentes antitumorales. | |
MXPA04004220A (es) | Derivados de quinazolina como agentes antitumorales. | |
MY158054A (en) | 4-anilino quinazoline derivatives as antiproliferative agents | |
HK1091486A1 (en) | Quinazoline derivatives | |
TW200512205A (en) | Quinazoline derivatives | |
MY138851A (en) | Quinazoline derivatives | |
TW200602328A (en) | Quinazoline derivatives | |
MY141739A (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
TW200519104A (en) | Quinazoline derivatives | |
HK1087613A1 (en) | Quinazoline derivatives and their use in the treatment of cancer | |
NO20060415L (no) | Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer | |
MXPA06003161A (es) | Derivados de quinazolina. | |
UA88012C2 (uk) | Похідні хіназоліндіону як інгібітори parp | |
IL180136A0 (en) | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer | |
MXPA03010207A (es) | Nuevas 4-anilinoquinolin-3-carboxamidas. | |
JO2339B1 (en) | Benzamidazole compounds | |
IL173348A (en) | Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs | |
MY127369A (en) | Quinazoline derivatives | |
MY141220A (en) | Pyrazole derivatives as inhibitors of receptor tyrosine kinases | |
GEP20074213B (en) | Novel inhibitors of kinases | |
TW200635923A (en) | Tricyclic heterocycles, their manufacture and use as pharmaceutical agents | |
GB0114286D0 (en) | Nucleoside Derivatives | |
PL367682A1 (en) | Dolastatin 10 derivatives | |
TW200624431A (en) | Phthalazinone derivatives, their manufacture and use as pharmaceutical agents | |
MY128924A (en) | Novel compounds |